Efficacy and safety of imatinib mesylate (Gleevec®) and immunohistochemical expression of c-Kit and PDGFR-β in a Gynecologic Oncology Group Phase Il Trial in women with recurrent or persistent carcinosarcomas of the uterus
Warner K. Huh(University of Alabama at Birmingham), Michael J. Birrer(University of Arkansas Medical Center), David M. O’Malley(The Ohio State University), John F. Boggess(University of Kentucky), Michael W. Sill(University at Buffalo, State University of New York), Kathleen M. Darcy(Gynecologic Oncology Group), Harry J. Long(Memorial Sloan Kettering Cancer Center), Kevin M. Elias(Harvard University), James Hoffman(University of Michigan), Ronald D. Alvarez(Vanderbilt University Medical Center)
Cited by 41
Related Papers
Integrated genomic analyses of ovarian carcinoma
|Nature|2011|8.2k
Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer
|Nature reviews. Cancer|2015|1.4k
<i>BRCA</i> Mutation Frequency and Patterns of Treatment Response in <i>BRCA</i> Mutation–Positive Women With Ovarian Cancer: A Report From the Australian Ovarian Cancer Study Group
|Journal of Clinical Oncology|2012|1.2k